Core Insights - Shandong Fukun Group's project on "Key Technologies and Industrialization of Crystalline Hydrochloride Metformin and Lazol Series Drugs" won the 2024 Shandong Provincial Science and Technology Progress Second Prize, achieving international advanced levels in high-quality drug crystal production [1] - The company has developed a complete industrial chain for Metformin, increasing its annual production capacity from 5,000 tons to 20,000 tons, capturing 70% of the domestic market and nearly one-third of the global market share [1][2] Group 1 - The project addresses common challenges in the production of crystalline Hydrochloride Metformin and Lazol series drugs through multi-scale research from molecular level to industrialization [1] - The fully automated production line at Shandong Fukun Group operates at a speed of 200 boxes per minute, showcasing advanced intelligent control systems monitoring the entire production process [1] - The transformation of limestone, costing 70 yuan per ton, into diabetes treatment drugs valued at 600,000 yuan per ton illustrates the company's innovative production capabilities [1] Group 2 - The company identified high-quality limestone from the Helan Mountain region as a stable raw material for producing Dicyandiamide, which constitutes over 60% of the production cost of Metformin [2] - In 2021, Shandong Fukun Group established the world's largest Dicyandiamide production base in Alxa League, Inner Mongolia, enhancing its upstream supply chain [2] - The company has formed a complete industrial chain that includes pharmaceutical intermediates, specialty raw materials, and finished formulations, with leading global production and sales in the raw material drug sector [2]

数据显示，8月15日国药一致主力资金净流出1837.68万元，近五日累计净流出1337.77万元。 风险提示：以上信息仅供参考，不构成任何投资建议。 该公司属于医药商业板块，是中国医药集团旗下拥有"分销+零售+工业投资"完整产业链的综合性医药上 市公司。其业务覆盖全国医药零售网络及两广地区分销网络，为全国医疗机构和零售终端提供医药供应 链服务。 根据公司披露的业绩快报，2025年上半年实现营业总收入367.97亿元，同比下降2.62%；归母净利润 6.66亿元，同比下降10.43%。值得注意的是，零售板块表现突出，实现净利润0.17亿元，同比增长 215.81%，主要得益于业务结构优化和经营质量提升。 国药一致最新股价报25.82元，较前一交易日上涨0.23元。盘中最高触及25.87元，最低下探25.58元，成 交金额达1.11亿元。 ...

齐鲁晚报.齐鲁壹点高松通讯员杜永武 一粒药片，承载生命的重量；一项技术，决定产业的未来。在山东医药产业高地上，"鲁南制药"四个字，以其厚重底蕴、创新活力和卓 越品质，成为一面鲜明的"山东好品牌"旗帜。 7月中下旬的鲁南制药生产车间，并非预想中的一派繁忙景象。在订单化式按量生产的运转模式下，不少车间完成任务后筹划暑期旅游。 唯有51车间，连续3年未曾停歇。 从沂蒙山区起步，鲁南制药更将目光投向全球医药科技的"星辰大海"。面对复杂的药物合成工艺、严苛的质量标准，鲁南制药人以"敢啃 硬骨头"的精神，一次次实现技术突破，72个制剂在129个国家和地区获批上市，将"山东制造"的可靠与"鲁南制药"的匠心，深深烙印在 每一粒药品之上。 畅销药产线三年未歇 产能挺身第一梯队 "从这个车间产出的克拉维酸钾，以每年1500吨产能，占全球用量的近三分之一，可以说排在世界第一。"鲁南制药集团副总经理刘忠颇 为自豪地亮出了数据。 在医学领域，克拉维酸钾常与阿莫西林组成复方片剂、注射剂、混悬剂等，可用于敏感菌引起的各种感染。自2006年克拉维酸钾原料药 上市后，鲁南制药为创新、维护这款药物专门组建研究团队持续服务。 "最近一次的研发主要 ...